Molecular mechanisms of psychostimulant addiction

Chang Gung Medical Journal

Volumn 32, Issue 2, 2009, Pages 148-154

  Chen, Jin Chung ^a   Chen, Pei Chun ^b   Chiang, Yao Chang ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

(meth) amphetamine; Dopamine; Drug addiction; Glutamate; Nucleus accumbens

Indexed keywords

COCAINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; METHADONE; NALTREXONE; NICOTINE GUM; NICOTINE PATCH; NICOTINE VACCINE; PHOSPHOPROTEIN DARPP 32; PROTEIN KINASE B; PSYCHOSTIMULANT AGENT; TRANSCRIPTION FACTOR FOSB;

ALCOHOLISM; BEHAVIOR DISORDER; DISEASE SEVERITY; DRUG DEPENDENCE; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; MOLECULAR MECHANICS; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; OPIATE ADDICTION; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; TOBACCO DEPENDENCE; UPREGULATION;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE-RELATED DISORDERS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOPAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; HUMANS; METHAMPHETAMINE; SIGNAL TRANSDUCTION; VENTRAL TEGMENTAL AREA;

EID: 64949182769     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci 2005;8:1445-9.
2. Vezina P. Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs. Neurosci Biobehav Rev 2004;27:827-39.
3. Paulson PE, Camp DM, Robinson TE. Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology 1991;103:480-92.
4. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 1986;ll:157-98.
5. Kalivas PW, Nakamura M. Neural systems for behavioral activation and reward. Curr Opin Neurobiol 1999;9:223- 7.
6. Borgkvist A, Fisone G. Psychoactive drugs and regulation of the cAMP/PKA/DARPP-32 cascade in striatal medium spiny neurons. Neurosci Biobehav Rev 2007;31:79-88.
7. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev 1991;16:223-44.
8. Cador M, Bjijou Y, Stinus L. Evidence of a complete independence of the neurobiological substrates for the induction and expression of behavioral sensitization to amphetamine. Neuroscience 1995;65:385-95.
9. Perugini M, Vezina P. Amphetamine administration to the ventral tegmental area sensitizes rats to the locomotor effects of nucleus accumbens amphetamine. J Pharmacol Exp Ther 1994;270:690-6.
10. Hooks MS, Jones GH, Liem BJ, Justice JB Jr. Sensitization and individual differences to intraperitoneal amphetamine, cocaine or caffeine following repeated intracranial amphetamine infusions. Pharmacol Biochem Behav 1992;43:815-23.
11. Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, cadoni C, Acquas E, Carboni E, Valentini V, Lecca D. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 2004;47:227-41.
12. Kalivas PW, Alesdatter JE. Involvement of NMDA receptor stimulation in the VTA and amygdala in behavioral sensitization to cocaine. J Pharmacol Exp Ther 1993;267:486-95.
13. 1 dopamine receptor activation is necessary for the induction of sensitization by amphetamine in the ventral tegmental area. J Neurosci 1996;16:2411-20.
14. Wolf ME, White FJ, Nassar R, Brooderson RJ, Khansa MR. Differential development of autoreceptor subsensitivity and enhanced dopamine release during amphetamine sensitization. J Pharmacol Exp Ther 1993;264:249- 55.
15. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 2006;29:565-98.
16. Jones S, Bonci A. Synaptic plasticity and drug addiction. Curr Opin Pharmacol 2005 ;5:20-5.
17. Wolf ME, Sun X, Mangiavacchi S, Chao SZ. Psychomotor stimulants and neuronal plasticity. Neuropharmacology 2004;47:61-79.
18. Carr DB, Sesack SR. Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci 2000;20:3864-73.
19. Malenka RC. Synaptic plasticity and AMPA receptor trafficking. Ann NY Acad Sci 2003;1003:1-11.
20. Bredt DS, Nicoll RA. AMPA receptor trafficking at excitatory synapses. Neuron 2003;40:361-79.
21. Montague PR, Hyman SE, Cohen JD. Computational roles for dopamine in behavioral control. Nature 2004;431:760-7.
22. Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science 1997;278:58-63.
23. Nestler EJ. From neurobiology to treatment: progress against addiction. Nat Neurosci 2002;5:1076-9.
24. Waters CL, Kuo YC, Blendy JA. Differential distribution of CREB in the mesolimbic dopamine reward pathway. J Neurochem 2003;87:1237-44.
25. Zhang XF, Odom DT, Koo SH, Conkright MD, Canettieri G, Best J, Chen HM, Jenner R, Herbolsheimer E, Jacobsen E, Kadam S, Ecker JR, Emerson B, Hogenesch JB, Unterman T, Young RA, Montminy M. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci USA 2005;102:4459- 64.
26. Impey S, McCorkle SR, Cha-Monlstad H, Dwyer JM, Yochum GS, Boss JM, McWeeney S, Dunn JJ, Mandel G, Goodman RH. Defining the CREB regulon: a genomewide analysis of transcription factor regulator regions. Cell2004;119:1041-54.
27. Cole RL, Konradi C, Douglass J, Hyman SE. Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striaturn. Neuron 1995;14:813-23.
28. Carlezon WA Jr, Duman RS, Nestler EJ. The many faces of CREB. Trends Neurosci 2005;28:436-45.
29. Olsen VG, Zabetian CP, Bolanos CA, Edwards S, Barrot M, Eisch AJ, Hughes T, Self DW, Neve RL, Nestler EJ. Regulation of drug reward by cAMP response elementbinding protein: evidence for two functionally distinct subregions of the ventral tegmental area. J Neurosci 2005;25:5553-62.
30. McClung CA, Ulery PG, Perrotti LI, Zachariou V, Berton O, Nestler EJ. AFosB: a molecular switch for long-term adaptation in the brain. Mol Brain Res 2004;132:146-54.
31. Peakman MC, Colby C, Perrotti LI, Tekumalla P, Carle T, Ulery P, Chao J, Duman C, Steffen C, Monteggia L, Allen MR, Stock JL, Duman RS, McNeish JD, Barrot M, Self DW, Nestler EJ, Schaffer E. Inducible, brain region specific expression of a dominant negative mutant of c-Jun in transgenic mice decreases sensitivity to cocaine. Brain Res 2003;970:73-86.
32. Drago J, Gerfen CR, Westphal H, Steiner H. Dl dopamine receptor-deficient mouse: cocaine-induced regulation of immediate-early gene and substance P expression in the striatum. Neuroscience 1996;74:813-23.
33. Neisewander JL, Fuchs RA, O'Dell LE, Khroyan TV. Effects of SCH23390 on dopamine Dl receptor occupancy and locomotion produced by intraaccumbens cocaine infusion. Synapse 1998;30:194-204.
34. Nishi A, Bibb JA, Snyder GL, Higashi H, Nairn AC, Greengard P. Amplification of dopaminergic signaling by a positive feedback loop. Proc Natl Acad Sci USA 2000;97:12840-5.
35. Bibb JA, Chen J, Taylor JR, Svenningsson P, Nishi A, Snyder GL, Yan Z, Sagawa ZK, Ouimet CC, Nairn AC, Nestler EJ, Greengard P. Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature 2001 ;410:376-80.
36. Svenningsson P, Fienberg AA, Allen PB, Le Moine C, Lindskog M, Fisone G, Greengard P, Fredholm BB. Dopamine Dl receptor-induced gene transcription is modulated by DARPP-32. J Neurochem 2000;75:248-57.
37. Fienberg AA, Hiroi N, Mermelsten P, Song WJ, Snyder GL, Nishi A, Cheramy A, O'Callaghan JP, Miller DB, Cole DG, Corbett R, Haile CN, Cooper DC, Onn SP, Grace AA, Ouimet CC, White FJ, Hyman SE, Surmeier DJ, Girault JA, Nestler EJ, Greengard P. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 1998;281:838-42.
38. Zachariou V, Sgambato-Faure V, Sasaki T, Svenningssn P, Berton O, Fienberg AA, Narin AC, Greengard P, Nestler EJ. Phosphorylation of DARPP-32 at threonine-34 is required for cocaine action. Neuropsychopharmacology 2006;31:555-62.
39. Chen PC, Chen JC. Enhanced Cdk5 activity and p35 translocation in the ventral striatum of acute and chronic methamphetamine-treated rats. Neuropsychopharmacology 2005;30:538-49.
40. Nishi A, Snyder GL, Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 1997;17:8147-55.
41. Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2001;2:119-28.
42. Beaulieu JM, Tirotta E, Sotnikova TD, Masri B, Salahpour A, Gainetdinov RR, Borrelli E, Caron MG. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 2007;27:881-5.
43. Beaulieu J-M, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR, Caron MG. Lithium antagonizes dopamine-dependent behaviors mediated by an Akt/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 2004;101:5099-104.
44. Emamian ES, Hall D, Bimbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired Aktl- GSK3p signaling in schizophrenia. Nat Genet 2004;36:131-7.
45. Beaulieu J-M, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005;122:261-73.
46. Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004;7:387-90.
47. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamateinduced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 1999;96:8745-50.
48. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001;41:789-813.
49. Shalev U, Grimm JW, Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev 2002;54:l-42.
50. Kantak KM, Collins SL, Bond J, Fox BS. Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology 2001; 153:334-40.
51. Cornish JL, Kalivas PW. Cocaine sensitization and craving: differing roles for dopamine and glutamate in the nucleus accumbens. J Addict Dis 2001;20:43-54.
52. 2-like dopamine receptor agonists. Science 1996;271: 1586-9.